Moderna’s stock climbed in after-hours trading while shares of Arbutus fell.

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Federal Circuit affirms PTAB ruling against Implicit, holding late inventorship correction cannot revive patent arguments in ...

Valve Corp.’s victory against an inventor under state laws penalizing bad-faith patent litigation highlights the importance of licensing agreement terms even if it falls short of heralding the end of ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

Oct 27 (Reuters) - Voice recognition technology company Parus has filed a malpractice lawsuit against law firm Mintz Levin, alleging that professional negligence by the firm led to the invalidation of ...

Who should read this article? Companies sued by patent trolls (NPEs) [1] seeking to develop strategies to push back against NPE activity—and specifically companies in the following industries: ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...